corpus.blog
56,966 blogs · 4,417,066 posts Claim your blog
Record · corpus.blog/posts/01a0e345-d541-734b-b156-d3d4f30ef6f9

How Zambia approved an HIV drug in 12 days

asteriskmag.substack.com · published 23 September 2026

A record is what was published and who pointed at it. The text of the post is not held here: read it at the source, or at its Wayback capture.

Read the post at asteriskmag.substack.com Wayback capture
0blogs citing
First cited
—
Most recent
—
Rank this month
not ranked
Links from this post
39
Words captured
3,898

Cited by

No blog we hold has cited this post yet.

Links from this post

Link
Host
https://substackcdn.com/image/fetch/$s_!U0I3!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F48cdc3d5-a51f-43be-8a65-acffa2908203_2000x401.png
substackcdn.com
https://www.tga.gov.au/about-us/careers
tga.gov.au
https://www.gilead.com/news/news-details/2012/us-food-and-drug-administration-approves-gileads-truvada-for-reducing-the-risk-of-acquiring-hiv
gilead.com
https://www.gilead.com/news/news-details/2024/full-efficacy-and-safety-results-for-gilead-investigational-twice-yearly-lenacapavir-for-hiv-prevention-presented-at-aids-2024
gilead.com
https://www.gilead.com/news/news-details/2024/gilead-presents-full-purpose-2-data-results-for-twice-yearly-lenacapavir-for-hiv-prevention-at-hiv-glasgow
gilead.com
https://www.science.org/content/article/breakthrough-2024
science.org
https://www.unaids.org/en/resources/documents/2024/global-aids-update-2024
unaids.org
https://substackcdn.com/image/fetch/$s_!FpKV!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa68be20a-e80a-4495-bb86-d0d40d8466d4_1000x833.png
substackcdn.com
https://www.who.int/initiatives/who-listed-authority-reg-authorities
who.int
https://substackcdn.com/image/fetch/$s_!RKs0!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2cc41b91-f15d-4142-bdd2-89c857d91ce3_1360x1000.svg
substackcdn.com
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/220018Orig1s000ltr.pdf
accessdata.fda.gov
https://www.gilead.com/company/company-statements/2025/gilead-submits-marketing-authorization-applications-to-european-medicines-agency-for-twice-yearly-lenacapavir-for-hiv-prevention
gilead.com
https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-procedural-advice-medicinal-products-intended-exclusively-markets-outside-european-union-context-co-operation-world-health-organisation-who_en.pdf
ema.europa.eu
https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/lenacapavir-gilead-assessment-report_en.pdf
ema.europa.eu
https://www.ema.europa.eu/en/news/new-injection-easier-prevention-hiv-infection-eu-worldwide
ema.europa.eu
https://extranet.who.int/prequal/sites/default/files/whopar_files/HA811%20part7v1.pdf
extranet.who.int
https://extranet.who.int/prequal/news/pqtmed-expanded-abridged-prequalification-pathways
extranet.who.int
https://extranet.who.int/prequal/sites/default/files/whopar_files/HA811%20part1v1.pdf
extranet.who.int
https://extranet.who.int/prequal/news/first-lenacapavirs-prequalified
extranet.who.int
https://doi.org/10.1016/j.jacbts.2016.03.002
doi.org
https://substackcdn.com/image/fetch/$s_!Y7TN!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd69cca95-277b-49c8-a27c-de58a0306eda.svg
substackcdn.com
https://www.who.int/publications/i/item/B09336
who.int
https://extranet.who.int/prequal/about
extranet.who.int
https://cdn.who.int/media/docs/default-source/medicines/regulatory-updates/fpi/sra-crp-participating-countries.pdf?sfvrsn=c247bee4_4
cdn.who.int
https://cdn.who.int/media/docs/default-source/medicines/regulatory-updates/rpq/who-rpq-impact-assessment-report_2023.pdf?sfvrsn=3b3a9b8_1
cdn.who.int
https://www.tandfonline.com/doi/full/10.1080/17512433.2020.1724782
tandfonline.com
https://www.ema.europa.eu/en/documents/other/article-58-strategic-review-summary_en.pdf
ema.europa.eu
https://doi.org/10.1371/journal.pone.0166515
doi.org
https://doi.org/10.1007/s43441-024-00730-6
doi.org
https://harddrugs.worksinprogress.co/episodes/lenacapavir-the-miracle-drug-that-could-end-aids
harddrugs.worksinprogress.co
https://doi.org/10.1016/S2352-3018(22
doi.org
https://www.gilead.com/news/news-details/2022/sunlenca-lenacapavir-receives-fda-approval-as-a-first-in-class-twice-yearly-treatment-option-for-people-living-with-multi-drug-resistant-hiv
gilead.com
https://doi.org/10.1007/s40290-017-0210-x
doi.org
https://doi.org/10.3389/fmed.2023.1265058
doi.org
https://www.fda.gov/international-programs/presidents-emergency-plan-aids-relief-pepfar/pepfar-database-frequently-asked-questions
fda.gov
https://www.gilead.com/news/news-details/2025/gilead-announces-partnership-with-pepfar-to-deliver-twice-yearly-lenacapavir-for-hiv-prevention-for-up-to-two-million-people-in-primarily-low--and-lower-middle-income-countries
gilead.com
https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/gmp
who.int
https://doi.org/10.1080/17512433.2022.2037419.
doi.org
https://www.raps.org/resource/ema-offers-parallel-article-58-centralized-authori.html
raps.org